Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
The author argues that long-term trends point to a future for physician assistants and nurse practitioners as the principal front-line deliverers of primary care, with physicians focusing on managerial duties and specialty care.